Abstract | INTRODUCTION:
Alopecia areata is a heterogenous, immune-mediated hair loss disorder that can affect any hair-bearing site on the body. Despite being one of the most prevalent autoimmune skin diseases, treatments have historically been limited to off-label medications that have demonstrated limited efficacy, especially in more severe forms of disease. Thus, there has long been an unmet need for rigorously studied therapeutics in alopecia areata. AREAS COVERED: EXPERT OPINION: The approval of baricitinib for treating severe alopecia areata marks a major milestone in the disease's history. While baricitinib has proven to be efficacious for this indication and has demonstrated an overall good safety profile, patients' individual risk factors for serious adverse events should be assessed during shared decision-making with patients before initiating treatment.
|
Authors | Colin M Kincaid, Justin D Arnold, Natasha A Mesinkovska |
Journal | Expert review of clinical immunology
(Expert Rev Clin Immunol)
Vol. 19
Issue 6
Pg. 565-573
(06 2023)
ISSN: 1744-8409 [Electronic] England |
PMID | 37042112
(Publication Type: Review, Journal Article)
|
Chemical References |
- baricitinib
- Sulfonamides
- Pyrazoles
|
Topics |
- Humans
- Alopecia Areata
(drug therapy, pathology)
- Sulfonamides
(therapeutic use)
- Pyrazoles
(therapeutic use)
|